Mod GRF (1-29) & GHRP-2 Blend (10mg)

Mod GRF (1-29) & GHRP-2 Blend (10mg): A Dual-Pathway Growth Hormone-Releasing Combination Combining a GHRH Receptor Agonist with a Ghrelin Receptor Agonist for Synergistic, Pulsatile GH Secretion in Research Settings

The Mod GRF (1-29) & GHRP-2 Blend is a co-lyophilized, 1:1 ratio peptide formulation that combines two well-characterized growth hormone (GH) secretagogues acting through complementary receptor pathways: Mod GRF (1-29) (also known as CJC-1295 without DAC), a tetrasubstituted analog of growth hormone-releasing hormone (GHRH) that binds and activates the GHRH receptor (GHRHR) on pituitary somatotrophs^[1]; and GHRP-2 (Pralmorelin), a synthetic hexapeptide growth hormone-releasing peptide that acts as a potent agonist at the ghrelin receptor (GHS-R1a), also expressed on somatotrophs^[2]. By simultaneously engaging both the GHRH receptor and the ghrelin receptor — the two primary physiological pathways that converge to stimulate GH release from the anterior pituitary — this blend is designed to produce a synergistic, amplified GH pulse that exceeds what either component alone can achieve^[3].

The scientific rationale for combining a GHRH analog with a GHRP is well established in the literature. Growth hormone secretion from the pituitary is regulated by two opposing hypothalamic hormones: GHRH, which stimulates GH release, and somatostatin, which inhibits it^[4]. Growth hormone-releasing peptides (GHRPs) such as GHRP-2 were later discovered to act through a distinct receptor — the ghrelin receptor — and to amplify GH release not only by direct somatotroph stimulation but also by suppressing somatostatin release from the hypothalamus^[5]. When GHRH and a GHRP are administered together, their effects on GH release are synergistic rather than merely additive, because they engage different intracellular signaling pathways (cAMP/PKA for GHRHR; PLC/IP3/PKC for GHS-R1a) that converge to increase intracellular calcium and GH exocytosis^[6].

Key Research Findings

1. Synergistic GH release: Clinical studies demonstrate that co-administration of GHRH and GHRP-2 produces GH peaks that are 2–3 times higher than either compound alone, confirming true synergistic interaction at the pituitary level^[3].
2. Mod GRF (1-29) stability: The D-Ala2, Ala8, Gln29 substitutions in Mod GRF (1-29) confer resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) and endopeptidases, extending its half-life to approximately 30 minutes — compared to less than 10 minutes for unmodified GHRH (1-29)^[7].
3. GHRP-2 potency: GHRP-2 is one of the most potent GHRPs, with GH-releasing activity comparable to or exceeding that of GHRP-6, but with less effect on appetite stimulation (because it does not significantly activate central orexigenic pathways at typical research doses)^[8].
4. Pulsatile secretion pattern: The combination of short-acting Mod GRF (1-29) with GHRP-2 produces a transient, pulsatile GH peak that more closely mimics physiological GH secretion patterns than continuous GH exposure — an important consideration for research examining the metabolic and tissue-specific effects of pulsatile vs. continuous GH signaling^[9].
5. Co-lyophilized formulation: This blend is co-lyophilized (both peptides lyophilized together in the same vial), ensuring homogeneous mixing and consistent 1:1 ratio in every dose, while maintaining the stability benefits of lyophilized powder storage at room temperature^[10].

References

1. Thorner MO, et al. Growth hormone-releasing hormone and its analogs. Endocrinology and Metabolism Clinics of North America. 1997;26(3):579-600. (GHRH receptor pharmacology)
2. Katakami H, et al. Pharmacological profile of pralmorelin (GHRP-2), a growth hormone-releasing peptide. Drugs of Today. 2007;43(3):171-182. (GHRP-2 clinical pharmacology)
3. Hataya Y, et al. Synergistic effects of growth hormone-releasing peptide-2 and growth hormone-releasing hormone on growth hormone secretion in humans. European Journal of Endocrinology. 2001;145(4):441-446. (Synergy study)
4. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 1998;19(6):717-797. (GH axis regulation review)
5. Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. (Ghrelin discovery)
6. Smith RG, et al. Growth hormone-releasing peptide (GHRP) cell and animal studies. Journal of Pediatrics. 1996;128(2 Pt 2):S29-S35. (GHRP mechanism review)
7. Martinez AG, et al. CJC-1295 and Ipamorelin: a review of growth hormone-releasing hormone analogs and growth hormone secretagogues. Journal of Medicinal Chemistry. 2022;65(12):8033-8051. (Mod GRF pharmacokinetics)
9. Pihoker C, et al. Effects of growth hormone-releasing peptide-2 (GHRP-2) and growth hormone-releasing hormone (GHRH) in children with short stature. Journal of Clinical Endocrinology & Metabolism. 1998;83(3):837-841. (GHRP-2 vs GHRP-6)
10. Veldhuis JD, et al. Pulsatile growth hormone secretion: mechanisms and physiological relevance. Recent Progress in Hormone Research. 2001;56:293-317. (Pulsatile GH physiology)
11. Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351-367. (Lyophilized peptide stability)